Tekmira files IND with FDA

Tekmira Pharmaceuticals (TSX:TKM) has filed an investigational new drug application seeking approval from the FDA to begin a Phase 1 clinical trial to evaluate PLK1 SNALP as a treatment for solid tumour cancers. “This is another important milestone for Tekmira as we continue to both advance our own pipeline of RNA-interference drug candidates and support our [...]

Tekmira’s leading RNAi platform ready for prime time

As a global leader in the emerging field of RNA interference (RNAi), which holds the potential of revolutionizing medicine with new therapeutics, upstart Tekmira Pharmaceuticals (TSX:TKM) is at the precipice of confirming that the highly touted science works in humans. “We really are at the crux,” CEO Dr. Mark Murray says in an exclusive interview [...]